* GENOMIC VISION *
2004 - IDF
Paris
www.genomicvision.com Discovery, Drugs
(also, Discovery, Diagnostics)
Key words: Diagnostics, Nanotechnology, DNA, Molecular combing
Mission: to develop novel diagnostic, biomarkers and drug discovery solutions based on proprietary nanotechnology for DNA analysis in the areas of cancer and acute diseases
Clients: Pharmaceutical industry (Sanofi-Aventis), Biotechs
a.bensimon@genomicvision.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.: Bensimon (Aaron) [born 1957, co-founder, Ph.D. molecular biology, ex-Institut Pasteur]
Sc.Dir.:
Oper.Dir.: Nerson (Daniel) [born 1958, co-founder, Ph.D., ex-Pasteur Mediavita, Dade-Behring]
Fin.Dir.:
BusDev:
Financers: Société Générale Asset Management Alternative Investments (SGAM AI), Vesalius BioCapital | Turnover (M€) : 0.02 (2007)
Total funding (M€) : 6.0
Last funding (M€) : 4.0
Focus : Multiple
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .10 | Financing (no interest loan) : 1.1 M€, by OSEO Innovation, on an antiviral programme (partnered with Cellectis, which gets 7.5 M€) | DEBT | [4 years] |
| 2008 .07 | 2nd round-financing : 4.0 M€, by Vesalius BioCapital and previous shareholder Société Générale Asset Management Alternative Investments (SGAM AI) | RFINB | [4 years] |
| 2005 .11 | 1st round-financing : 2.0 M€, by Société Générale Asset Management (SGAM) | RFINA | [1 year] |
| 2004 .07 | Company founded by Aaron Bensimon (board chairman, CEO) and Daniel Nerson (COO) | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
